Aveo Oncology

Aveo Oncology’s kidney cancer drug gets FDA nod, 8 years after stinging rejection

In two pivotal studies years apart, Aveo Oncology’s drug tivozanib did not help kidney cancer patients live longer overall compared to the standard of care. The FDA approved still approved it, the latest development in a long saga that includes several regulatory stumbles.

By Frank Vinluan

BioPharma

AVEO Oncology puts off seeking FDA approval for kidney cancer drug until 1Q20

The agency told the company it still had lingering reservations about the results of a Phase III trial that had been designed to allay agency concerns. Shares of the company fell 38 percent on the news.

By Alaric DeArment

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.